Allergy experts: `Clinical effect of ALK`s tree SLIT-tablet among the most significant ever seen in allergy immunotherapy trials`
(WorldNews Denmark)

Leading allergy researchers present Phase III data on tree SLIT-tablet at EAACI Annual Congress in Munich Birch pollen-based product shown to be effective against multiple tree allergies Effect shown to be comparable across the entire birch, alder and hazel pollen season. ALK today announced that leading allergy researchers at a company-sponsored symposium have been the first to be presented with the full clinical and immunological data from a recent Phase III clinical trial of its new investigational tree sublingual allergy immunotherapy (SLIT) tablet. The symposium took place in Munich, Germany, as part of the Annual Congress of the European Academy of Allergy and Clinical Immunology...